Marker Therapeutics (MRKR) Competitors $1.23 +0.02 (+1.65%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.23 0.00 (0.00%) As of 08/7/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. INMB, BMEA, INKT, IFRX, DRRX, BRNS, CUE, PYRGF, ICCC, and ANLShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include INmune Bio (INMB), Biomea Fusion (BMEA), MiNK Therapeutics (INKT), InflaRx (IFRX), DURECT (DRRX), Barinthus Biotherapeutics (BRNS), Cue Biopharma (CUE), PyroGenesis Canada (PYRGF), ImmuCell (ICCC), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Its Competitors INmune Bio Biomea Fusion MiNK Therapeutics InflaRx DURECT Barinthus Biotherapeutics Cue Biopharma PyroGenesis Canada ImmuCell Adlai Nortye INmune Bio (NASDAQ:INMB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Do analysts rate INMB or MRKR? INmune Bio presently has a consensus price target of $18.40, suggesting a potential upside of 559.50%. Marker Therapeutics has a consensus price target of $13.17, suggesting a potential upside of 970.46%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Is INMB or MRKR more profitable? INmune Bio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -224.46%. Marker Therapeutics' return on equity of -101.87% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -119.35% -89.37% Marker Therapeutics -224.46%-101.87%-83.02% Do insiders and institutionals have more ownership in INMB or MRKR? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 35.7% of INmune Bio shares are held by insiders. Comparatively, 14.5% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, INMB or MRKR? Marker Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K6,578.82-$42.08M-$1.93-1.45Marker Therapeutics$6.59M2.11-$10.73M-$1.33-0.92 Does the media favor INMB or MRKR? In the previous week, INmune Bio had 8 more articles in the media than Marker Therapeutics. MarketBeat recorded 8 mentions for INmune Bio and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 beat INmune Bio's score of -0.34 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Neutral Marker Therapeutics Neutral Which has more volatility & risk, INMB or MRKR? INmune Bio has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. SummaryMarker Therapeutics beats INmune Bio on 12 of the 17 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.69M$2.51B$5.48B$9.57BDividend YieldN/A1.78%4.00%4.18%P/E Ratio-0.9219.6629.8825.14Price / Sales2.11684.52440.19102.95Price / CashN/A165.0335.9458.58Price / Book0.714.198.105.59Net Income-$10.73M$31.61M$3.26B$265.48M7 Day Performance-8.89%0.95%0.65%1.22%1 Month Performance-23.13%2.90%2.44%0.39%1 Year Performance-68.38%4.11%27.59%23.47% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.2019 of 5 stars$1.23+1.7%$13.17+970.5%-67.5%$13.69M$6.59M-0.9260Upcoming EarningsINMBINmune Bio2.3544 of 5 stars$2.86+11.7%$18.40+543.4%-60.4%$60.38M$10K-1.4810Earnings ReportHigh Trading VolumeBMEABiomea Fusion3.6932 of 5 stars$1.61+2.5%$20.10+1,148.4%-71.8%$58.99MN/A-0.4550News CoverageEarnings ReportAnalyst ForecastGap UpINKTMiNK Therapeutics2.4358 of 5 stars$13.22-10.2%$37.50+183.7%+50.9%$58.67MN/A-5.2530Upcoming EarningsIFRXInflaRx3.2534 of 5 stars$0.89+3.3%$6.60+642.9%-41.8%$57.74M$180K-1.0860News CoverageGap DownDRRXDURECT1.0224 of 5 stars$1.86+1.4%N/A+43.5%$56.96M$2.03M-12.4080Upcoming EarningsBRNSBarinthus Biotherapeutics2.4395 of 5 stars$1.29-7.9%$6.25+384.5%+4.3%$56.47M$14.97M-0.79107News CoverageNegative NewsEarnings ReportGap DownCUECue Biopharma3.8556 of 5 stars$0.76+3.4%$4.00+424.9%+19.1%$55.55M$9.29M-1.1460News CoverageUpcoming EarningsPYRGFPyroGenesis Canada0.3491 of 5 stars$0.29+2.9%N/A-47.6%$54.55M$9.14M-4.8590ICCCImmuCell0.0634 of 5 stars$6.24+4.0%N/A+63.7%$54.22M$26.49M-89.1370News CoverageUpcoming EarningsANLAdlai Nortye1.7433 of 5 stars$1.50+3.4%$9.00+500.0%-50.2%$53.51M$5M0.00127Upcoming EarningsGap Up Related Companies and Tools Related Companies INmune Bio Alternatives Biomea Fusion Alternatives MiNK Therapeutics Alternatives InflaRx Alternatives DURECT Alternatives Barinthus Biotherapeutics Alternatives Cue Biopharma Alternatives PyroGenesis Canada Alternatives ImmuCell Alternatives Adlai Nortye Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
